Fractomer Biomatrix for Tissue Reconstruction
Breast Reconstruction (e.g., post-mastectomy)
Key Facts
About InSoma Bio
InSoma Bio is a private, preclinical-stage biotech founded in 2019, leveraging a proprietary biomaterials platform to create next-generation solutions for tissue reconstruction. The company's 'Fractomer Biomatrix' is an injectable, thermally-activated material produced via recombinant protein engineering, aiming to improve outcomes in autologous tissue reconstruction. With a founding team combining deep academic expertise in biomedical engineering from Duke University and clinical leadership in plastic surgery, the company is positioned to address significant unmet needs in the reconstructive surgery market. Recent activities include participation in the MedTech Innovator 2025 program and strategic board appointments.
View full company profileAbout InSoma Bio
InSoma Bio is a private, preclinical-stage biotech founded in 2019, leveraging a proprietary biomaterials platform to create next-generation solutions for tissue reconstruction. The company's 'Fractomer Biomatrix' is an injectable, thermally-activated material produced via recombinant protein engineering, aiming to improve outcomes in autologous tissue reconstruction. With a founding team combining deep academic expertise in biomedical engineering from Duke University and clinical leadership in plastic surgery, the company is positioned to address significant unmet needs in the reconstructive surgery market. Recent activities include participation in the MedTech Innovator 2025 program and strategic board appointments.
View full company profile